Inmune Bio INMB
NASDAQ INMB
$1.10 +0.00 (+0.00%)
At close: Nov 11, 2026 · 4:00 PM EST

Inmune Bio (INMB) Preferred Stock Liabilities (2023 - 2024)

Updated

Inmune Bio's Preferred Stock Liabilities came in at $799,000 for Q2 2024, unchanged from the prior quarter.

Analysis

Inmune Bio (INMB) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends

Going back to Q3 2023, Inmune Bio's Preferred Stock Liabilities data covers 4 quarters.

  • Business Quant data shows INMB's Preferred Stock Liabilities at $799,000 (Q1 2024), $799,000 (Q4 2023) and $799,000 (Q3 2023) in the three quarters before Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Inmune Bio 30.71 Mn -50.14 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 799,000.00
Jun 30, 2024 799,000.00
Mar 31, 2024 799,000.00
Dec 31, 2023 799,000.00
Sep 30, 2023 799,000.00
API Access

Inmune Bio Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=INMB&period=max&api_key=YOUR_API_KEY